Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Ensysce Biosciences, Inc. ENSC NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
51/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Ensysce Biosciences, Inc. (ENSC) is a Biotechnology company in the Healthcare sector, currently trading at $0.52. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Valuation: ENSC trades at a trailing Price-to-Earnings (P/E) of -0.1 (S&P 500 average ~25).

Net income is $10.2T (loss), growing at -42467699.8%/yr. Net profit margin is 0% (thin). Gross margin is 100% (+786.2 pp trend).

Balance sheet: total debt is $306.7B against $3.2T equity (Debt-to-Equity (D/E) ratio 0.1, conservative). Current ratio is 1.59 (strong liquidity). Debt-to-assets is 4.1%. Total assets: $7.5T.

Analyst outlook: 2 / 2 analysts rate ENSC as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 40/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 50/100 (Partial), Future 100/100 (Pass), Income ?/100 (Fail).

ENSC SharesGrow Score Overview

64/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 40/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ENSC

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
40/100
ENSC: +7.3%/yr revenue is, -42467699.8%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet ENSC: Debt-to-Equity (D/E) ratio 0.1 (conservative), Current ratio is 1.59 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
50/100
ENSC: Gross margin is 100% (+786.2 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 2 / 2 analysts rate ENSC as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.314-4.85
Volume201.45K
Avg Volume (30D)6.24M
Market Cap$4.82M
Beta (1Y)1.16
Share Statistics
EPS (TTM)-3.98
Shares Outstanding$2.56M
IPO Date2018-03-14
Employees7
CEOD. Lynn Kirkpatrick
Financial Highlights & Ratios
EBITDA$-10.15M
Net Income$-10.18T
Operating Income$-10.24T
Total Cash$4.31T
Total Debt$306.71B
Net Debt$-4T
Total Assets$7.45T
Price / Earnings (P/E)-0.1
Analyst Forecast
Rating ConsensusBuy
Analysts Covering2
Buy 100% Hold 0% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS2936025046

Price Chart

Track all markets on TradingView
ENSC
Ensysce Biosciences, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
0.31 52WK RANGE 4.85

People Also View

ATNF
ATNF
180 Life Sciences Corp.
$7.04
-7.49%
 ZURA
ZURA
Zura Bio Limited
$5.72
+0.70%
 ALLR
ALLR
Allarity Therapeutics, Inc.
$1.19
-0.76%
 PHIO
PHIO
Phio Pharmaceuticals Corp.
$1.29
+4.03%
 KPRX
KPRX
Kiora Pharmaceuticals, Inc.
$2.44
-0.33%
 SONN
SONN
Sonnet BioTherapeutics Holdings, Inc.
$1.26
-59.35%
 REVB
REVB
Revelation Biosciences, Inc.
$1.20
+0.84%
 HILS
HILS
Hillstream BioPharma, Inc.
$0.24
+5.66%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message